Also, we anticipate that the outcomes using this RCT will guide the development of other medical trials and larger effectiveness researches of positive psychology interventions in vulnerable oncological populations beyond HSCT. Oxaliplatin is a key chemotherapeutic representative when you look at the treatment of local and metastatic gastrointestinal (GI) malignancies. Dose density and therapy adherence may be limited by chemotherapy-induced peripheral neuropathy (CIPN). Early research recommends CIPN incidence and extent may be mitigated by acupuncture, but thorough data in GI oncology patients is restricted. Here, we describe the protocol of a randomized, waitlist-controlled pilot research testing the utilization of preemptive of acupuncture therapy plus acupressure to reduce CIPN and chemotherapy-related toxicities. Patients with a GI malignancy (n=56) with planned 5-fluorouracil (5-FU) and oxaliplatin IV (FOLFOX, FOLFIRINOX) every 2weeks are being recruited. Additional concurrent anti-neoplastic agents can be utilized. Enrolled patients are randomized 11 to a 3-month intervention of supply A acupuncture with acupressure and standard-of-care therapy, or supply B standard-of-care alone. In Arm A, on days 1 and 3 of every chemotherapy pattern a standardized acupuncture protocol Arm A acupuncture with acupressure and standard-of-care therapy, or supply B standard-of-care alone. In Arm A, on days 1 and 3 of each chemotherapy period a standardized acupuncture therapy protocol is administered and clients are taught self-acupressure to do daily between chemotherapy treatments. Clients in both hands receive standard-of-care dental and peripheral (hands/feet) ice processor chip cryotherapy during oxaliplatin administration. CIPN along with other symptoms tend to be considered at standard, 6 weeks, and a couple of months from registration. The principal endpoint is CIPN severity at three months (EORTC-CIPN 20). Additional endpoints evaluate CIPN incidence (CTCAE, Neuropen, tuning hand); occurrence of discomfort, fatigue, nausea, dental dysesthesia, and anxiety; and feasibility (recruitment, retention, adherence, acceptability). If warranted, trial results will notify the style of a multi-center test to grow screening regarding the input to a larger client cohort.Aging populations have reached increased risk of sleep deficiencies (e.g., sleeplessness) which can be involving many different persistent health problems, including Alzheimer’s disease vitamin biosynthesis illness and associated dementias (ADRD). Insomnia medicines carry extra risk, including increased drowsiness and falls, in addition to polypharmacy dangers. The advised first-line treatment for sleeplessness is cognitive behavioral treatment for sleeplessness (CBTi), but access is bound. Telehealth is the one solution to boost access, particularly for older grownups, but up to now telehealth happens to be usually limited to quick videoconferencing portals. While these portals have-been proved to be non-inferior to in-person therapy, it really is possible that telehealth could be significantly improved. This work defines a protocol built to assess whether a clinician-patient dashboard inclusive of several user-friendly features (e.g., patterns of sleep data from ambulatory devices, guided leisure resources, and reminders to perform in-home CBTi rehearse) could enhance CBTi outcomes for middle- to older-aged adults (N = 100). Individuals were randomly assigned to at least one Trimmed L-moments of three telehealth treatments delivered through 6-weekly sessions (1) CBTi augmented with a clinician-patient dashboard, smartphone application, and integrated wise devices; (2) standard CBTi (for example., active comparator); or (3) sleep hygiene training (in other words., active control). All individuals were assessed at assessment, pre-study assessment, baseline, throughout therapy, and at 1-week post-treatment. The principal outcome is the Insomnia Severity Index. Secondary and exploratory effects span rest journal, actiwatch and Apple view evaluated sleep parameters (age.g., effectiveness, duration, time, variability), psychosocial correlates (age.g., fatigue, depression, stress), intellectual performance find more , therapy adherence, and neurodegenerative and systemic inflammatory biomarkers. Poor diet quality is an important threat element for increased asthma prevalence and poor symptoms of asthma control. To deal with issue of whether grownups with symptoms of asthma can benefit from after a healthy diet, this test will test the efficacy and systems of activity of a behavioral intervention promoting the Dietary Approaches to avoid Hypertension (DASH) nutritional design with sodium decrease among customers with uncontrolled symptoms of asthma. In this 2-arm randomized medical trial, 320 racially/ethnically and socioeconomically diverse grownups with uncontrolled asthma on standard operator treatment will likely to be randomized to either a control or an input group and examined at baseline, 3, 6 and 12months. Control and input individuals will receive training on lung wellness, symptoms of asthma, as well as other general health subjects; additionally, the intervention group will receive DASH behavioral counseling over 12months. The primary hypothesis is that the DASH behavioral intervention, in contrast to the education-only control, will lead to significantly more participants with minimal medically important enhancement (responders) in asthma-specific lifestyle at 12months. Secondary hypotheses will test the input impacts on various other symptoms of asthma (e.g., symptoms of asthma control, lung function) and non-asthma effects (age.g., quality of life). Also, healing (e.g., brief string fatty acids, cytokines) and nutritional biomarkers (age.g., dietary inflammatory index, carotenoids) will undoubtedly be evaluated to comprehend the systems associated with intervention result. This trial can significantly advance symptoms of asthma treatment by giving rigorous proof regarding the great things about a behavioral dietary intervention and mechanistic ideas into the role of diet high quality in symptoms of asthma.